Santhera Pharmaceuticals Holding

Company snapshot

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Santhera Pharmaceuticals Holding. Not investment advice.

• What is Santhera Pharmaceuticals Holding?

  Santhera Pharmaceuticals (Deutschland) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Systemic Lupus Erythematosus. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Cl

• Is Santhera Pharmaceuticals Holding publicly traded?

  Santhera Pharmaceuticals Holding appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Santhera Pharmaceuticals Holding develop or market?

  We link 1 drug profile(s) where Santhera Pharmaceuticals Holding is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/santhera-pharmaceuticals-deutschland-gmbh#company-drugs.

• What are the latest developments for Santhera Pharmaceuticals Holding?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Santhera Pharmaceuticals Holding focus on?

  Santhera Pharmaceuticals Holding focuses on Systemic Lupus Erythematosus based on our analysis of their pipeline programs and drug development activities.